Microfluidic selection of monoclonal antibodies

单克隆抗体的微流控选择

• 批准号: 7482082
• 负责人: MICHAEL P WEINER
• 金额: $ 11.14万
• 依托单位: AFFOMIX, INC.
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-05-05 至 2010-05-04
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7482082
• 关键词: Affect; Alzheimer' s Disease; Antibodies; Antibody Affinity; Antigens; Attention; Bacteriophages; Binding; Biological Markers; Biological Process; Bite; Cataloging; Catalogs; Cells; Complement; Constriction procedure; DNA Sequence; Data; Development; Diabetes Mellitus; Diagnosis; Diagnostic; Disease; Dyes; Emulsions; Encapsulated; Enzyme-Linked Immunosorbent Assay; Facility Construction Funding Category; Figs - dietary; Fluorescence; Future; Genes; Genome; Genomics; Goals; Human; Human Genome Project; Immunotherapeutic agent; Incubated; Individual; Label; Libraries; Malignant Neoplasms; Measures; Methods; Microfluidics; Monoclonal Antibodies; Peptides; Phage Display; Production; Proteins; Proteome; Reagent; Research; Research Personnel; Risk; Scientist; Screening procedure; Small Business Technology Transfer Research; Solutions; Sorting - Cell Movement; Specificity; Staining method; Stains; Technology; Time; Tissues; United States National Institutes of Health; Universities; Yeasts; base; design; innovative technologies; instrument; interest; new technology; novel therapeutics; prognostic; response; therapeutic target; yeast two hybrid system

DESCRIPTION (provided by applicant): Nearly 20 years ago, partially as a response to leveraging the genomics research the NIH invested in the development of gene array technologies. These `gene chips' enabled great breakthroughs in our understanding of the underlying biological processes that occur in cells and tissues. These increased understandings have already led to new therapies that affect the way we now successfully treat and diagnose major diseases, including cancer, diabetes and Alzheimer's. But genes have always been a poor surrogate for what scientists are really eager to understand; the protein make-up and interactions occurring both within and between cells and tissues. In this proposal we describe a microfluidics-based method for obtaining antibodies and affinity-reagents that can be developed for making antibody arrays. We want to develop an inexpensive high-throughput means of selecting and identifying antibodies to both unmodified and modified protein and peptide antigens. The successful completion of this STTR and our future goals will have significant direct impact on the development of new therapeutic targets, new immunotherapeutics, and prognostics and diagnostic biomarkers.

描述（由申请人提供）：近20年前，部分作为对利用基因组学研究的响应，NIH投资于基因阵列技术的开发。这些“基因芯片”使我们对细胞和组织中发生的潜在生物过程的理解取得了重大突破。这些增加的理解已经导致了新的疗法，影响了我们现在成功治疗和诊断重大疾病的方式，包括癌症，糖尿病和阿尔茨海默氏症。但是基因一直是科学家们真正渴望了解的东西的一个糟糕的替代品;蛋白质的组成和细胞和组织内部和之间的相互作用。在该提案中，我们描述了一种基于微流体的方法，用于获得抗体和亲和试剂，可以开发用于制造抗体阵列。我们希望开发一种廉价的高通量方法来选择和鉴定针对未修饰和修饰的蛋白质和肽抗原的抗体。该STTR的成功完成和我们未来的目标将对新的治疗靶点、新的免疫治疗剂、免疫学和诊断生物标志物的开发产生重大的直接影响。